Keyphrases
CD4 T Cells
100%
Antitumor
100%
Peptide Vaccine
100%
Vaccination Strategy
80%
Peptide Vaccination
40%
Toll-like
20%
Cost-effectiveness
20%
Cell-based
20%
Mouse Model
20%
Antitumor T Cells
20%
Cancer Types
20%
Costimulation
20%
CD40
20%
Immune Tolerance
20%
Receptor Agonist
20%
Malignant Melanoma
20%
Synthetic Peptides
20%
Antitumor Effect
20%
Immunogenic
20%
Mouse Tumor Model
20%
Anti-melanoma
20%
CD8+ T Cell Response
20%
Anti-apoptotic
20%
Effective Approach
20%
Implementation Outcomes
20%
Tumor Antigen
20%
CD4+ T Lymphocytes
20%
Substantial Evidence
20%
Proliferative Activity
20%
Therapeutic Effectiveness
20%
OX40
20%
Lymphodepletion
20%
Ease of Implementation
20%
Immunology and Microbiology
T-Helper Cell
100%
Peptide Vaccine
100%
Vaccination Policy
80%
Immunotherapy
60%
T Cell
40%
Mouse
20%
Mouse Model
20%
CD4
20%
Immune Tolerance
20%
Cytotoxic T-Cell
20%
Agonist
20%
T Helper Cell
20%
Tumor Antigen
20%
Toll-Like Receptor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Peptide Vaccine
100%
Vaccination Policy
80%
Immunotherapy
60%
Mouse
20%
Malignant Neoplasm
20%
Antiapoptotic
20%
Mouse Model
20%
CD8 Antigen
20%
Melanoma
20%
Tumor Model
20%
Toll Like Receptor Agonist
20%
Tumor Antigen
20%
Synthetic Peptide
20%